PTPRC and myelodysplastic syndrome: Flow cytometry and IHC revealed that, compared with those from the untreated controls, BM (Fig. 3b) and splenic (Extended Data Fig. 9e and Supplementary Fig. 8c) samples from MDS-L xenograft mice treated with one cycle of ABT-199 (100 mg per kilogram body weight per day for 14 d) alone or in combination with 5-aza (0.5 mg per kilogram body weight per day on days 1–7 of a 28-d cycle; Supplementary Fig. 8b) had significantly fewer human CD45+ cells, which suggests that this therapy is effective in depleting the blast population.